MedTrace Logo

Study of cardiovAscular Contrasted Phenotypes in Patients With FamIliaI hypercholesteRolemia

NCT03234127 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 562

Last updated 2021-05-24

No results posted yet for this study

Summary

The main objective of SAFIR is to identify the atherosclerotic genetic factors in these patients, which will identify new therapeutic targets for the treatment of CV and Familial Hypercholesterolemia diseases. In addition, SAFIR will allow the identification of new CV protection biomarkers, which will be useful tools for the development of a personalized medicine for the management of dyslipidemias.

Conditions

  • Homozygous Familial Hypercholesterolemia

Interventions

GENETIC

Whole Genome Sequencing

Whole Genome Sequencing Biomarkers analyses

Sponsors & Collaborators

  • Nantes University Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-06
Primary Completion
2021-05-06
Completion
2021-05-06

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03234127 on ClinicalTrials.gov